Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -8.14% is 87% above its 5-year average of -64.85%, near the high end of its 5-year range (-123.81%–-8.14%).
73.04% above its 12-month average of -30.20%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-06-30): -0.79%.
RETURN ON ASSETS (ROA)
-8.14%
RETURN ON ASSETS (ROA) AVG TTM
-30.20%
RETURN ON ASSETS (ROA) AVG 3Y
-72.84%
RETURN ON ASSETS (ROA) AVG 5Y
-64.85%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+73.04%
CURRENT VS 3Y AVG
+88.83%
CURRENT VS 5Y AVG
+87.45%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 789 covered companies
CURRENT VS SECTOR MEDIAN
+74.05%
vs the sector median at left
Bright Minds Biosciences Inc.
Market Cap
$472.03M
Return on Assets (ROA)
-8.14%
TTM Avg
-30.20%
3Y Avg
-72.84%
5Y Avg
-64.85%
Market Cap
$471.02M
Return on Assets (ROA)
-22.99%
TTM Avg
-20.77%
3Y Avg
-18.00%
5Y Avg
-22.63%
Market Cap
$469.63M
Return on Assets (ROA)
5.81%
TTM Avg
4.61%
3Y Avg
2.71%
5Y Avg
3.04%
Market Cap
$475.60M
Return on Assets (ROA)
-3.31%
TTM Avg
-8.72%
3Y Avg
-14.01%
5Y Avg
-17.66%
Market Cap
$468.08M
Return on Assets (ROA)
-28.37%
TTM Avg
-34.70%
3Y Avg
-35.80%
5Y Avg
-35.55%
Market Cap
$477.13M
Return on Assets (ROA)
1.38%
TTM Avg
-14.74%
3Y Avg
-19.98%
5Y Avg
-18.10%
Market Cap
$459.97M
Return on Assets (ROA)
4.30%
TTM Avg
13.65%
3Y Avg
19.24%
5Y Avg
21.45%
Market Cap
$486.34M
Return on Assets (ROA)
13.86%
TTM Avg
14.29%
3Y Avg
9.48%
5Y Avg
0.09%
Market Cap
$487.98M
Return on Assets (ROA)
-13.84%
TTM Avg
-22.27%
3Y Avg
-29.75%
5Y Avg
-35.86%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bright Minds Biosciences Inc. (DRUG) | $472.03M | -8.14% | -30.20% | -72.84% | -64.85% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $471.02M | -22.99% | -20.77% | -18.00% | -22.63% |
| Kamada Ltd. (KMDA)vs › | $469.63M | 5.81% | 4.61% | 2.71% | 3.04% |
| Cerus Corporation (CERS)vs › | $475.60M | -3.31% | -8.72% | -14.01% | -17.66% |
| Sight Sciences, Inc. (SGHT)vs › | $468.08M | -28.37% | -34.70% | -35.80% | -35.55% |
| Arvinas, Inc. (ARVN)vs › | $477.13M | 1.38% | -14.74% | -19.98% | -18.10% |
| NRC Health (NRC)vs › | $459.97M | 4.30% | 13.65% | 19.24% | 21.45% |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.34M | 13.86% | 14.29% | 9.48% | 0.09% |
| Evolus, Inc. (EOLS)vs › | $487.98M | -13.84% | -22.27% | -29.75% | -35.86% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $448.58M | -83.42% | -53.06% | -45.42% | -42.54% |
ROA
-8.1%
ROE
-8.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-09-30 | -14.49% |
| 2024-09-30 | -45.90% |
| 2023-09-30 | -107.17% |
| 2022-09-30 | -123.81% |
| 2021-09-30 | -43.17% |
| 2020-09-30 | -54.57% |
| 2019-09-30 | -144.02% |
